[go: up one dir, main page]

ATE353221T1 - Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa - Google Patents

Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa

Info

Publication number
ATE353221T1
ATE353221T1 AT01976574T AT01976574T ATE353221T1 AT E353221 T1 ATE353221 T1 AT E353221T1 AT 01976574 T AT01976574 T AT 01976574T AT 01976574 T AT01976574 T AT 01976574T AT E353221 T1 ATE353221 T1 AT E353221T1
Authority
AT
Austria
Prior art keywords
oral
treatment
intestinal mucosa
agents
candida
Prior art date
Application number
AT01976574T
Other languages
English (en)
Inventor
Giancarla Dondi
Original Assignee
Proge Farm Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proge Farm Srl filed Critical Proge Farm Srl
Application granted granted Critical
Publication of ATE353221T1 publication Critical patent/ATE353221T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01976574T 2000-11-02 2001-10-29 Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa ATE353221T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2000MI002369A IT1320772B1 (it) 2000-11-02 2000-11-02 Composizione farmaceutica a base di agenti attivi contro la candidaper il trattamento di disturbi della mucosa orale e intestinale

Publications (1)

Publication Number Publication Date
ATE353221T1 true ATE353221T1 (de) 2007-02-15

Family

ID=11446081

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01976574T ATE353221T1 (de) 2000-11-02 2001-10-29 Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa

Country Status (7)

Country Link
US (1) US20040043011A1 (de)
EP (1) EP1339419B1 (de)
AT (1) ATE353221T1 (de)
AU (1) AU2001295839A1 (de)
DE (1) DE60126504T2 (de)
IT (1) IT1320772B1 (de)
WO (1) WO2002036137A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1384483A1 (de) * 2002-07-23 2004-01-28 Nestec S.A. Probiotische Mikroorganismen zur Behandlung von Colon Irritabile durch die Verbesserung der neuromuskulären Darmfunktion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6855M (de) * 1967-12-18 1969-04-08
US4839281A (en) * 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
ZA935111B (en) * 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
GB9302567D0 (en) * 1993-02-10 1993-03-24 Smithkline Beecham Plc Novel compound
IT1299070B1 (it) * 1998-04-10 2000-02-07 Proge Farm Srl Ceppi di lattobacilli capaci di inibire e/o avere azione microbicida nei confronti di microorganismi patogeni e metodo di induzione e
EP0904784A1 (de) * 1997-09-22 1999-03-31 N.V. Nutricia Probiotisches Ernährungspräparat
US5981499A (en) * 1998-02-20 1999-11-09 Atlantic Biomed Corporation Lesion-directed antibiotics in dry dosage forms for the treatment of shallow ulcers of the oral mucosa
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius

Also Published As

Publication number Publication date
WO2002036137A1 (en) 2002-05-10
EP1339419A1 (de) 2003-09-03
DE60126504T2 (de) 2007-11-22
US20040043011A1 (en) 2004-03-04
AU2001295839A1 (en) 2002-05-15
DE60126504D1 (de) 2007-03-22
EP1339419B1 (de) 2007-02-07
ITMI20002369A1 (it) 2002-05-02
IT1320772B1 (it) 2003-12-10

Similar Documents

Publication Publication Date Title
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
HUP0301868A2 (hu) Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
MA27311A1 (fr) Utilisation d'inhibiteurs de cetp et facultativement d'inhibiteurs de hmg-coa-reductase et/ou d'agents antihypertensifs
BR0307508A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
NO20053855L (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
EE05423B1 (et) IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon
BG105302A (en) Means for improving cognition
BR0313239A (pt) Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de doenças
BR0014355A (pt) Derivados de sapogenina e seu uso no tratamento de disfunção cognitiva
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
ATE400277T1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
SE0001916D0 (sv) Novel formulation
RS60604A (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE353221T1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
DE60117541D1 (de) Candesartan zur Behandlung von Migräne
BR0005319A (pt) Tratamento combinado para depressão e ansiedade
DE60212349D1 (de) Verwendung von n-acetyl-d-glucosamin bei der herstellung eines pharmazeutischen mittels zur prävention und behandlung von sexuellen störungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties